GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (NYSE:ZBH) » Definitions » ROE %

Zimmer Biomet Holdings (Zimmer Biomet Holdings) ROE %

: 13.42% (As of Dec. 2023)
View and export this data going back to 2001. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Zimmer Biomet Holdings's annualized net income for the quarter that ended in Dec. 2023 was $1,677 Mil. Zimmer Biomet Holdings's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $12,496 Mil. Therefore, Zimmer Biomet Holdings's annualized ROE % for the quarter that ended in Dec. 2023 was 13.42%.

The historical rank and industry rank for Zimmer Biomet Holdings's ROE % or its related term are showing as below:

ZBH' s ROE % Range Over the Past 10 Years
Min: -3.3   Med: 3.18   Max: 16.95
Current: 8.32

During the past 13 years, Zimmer Biomet Holdings's highest ROE % was 16.95%. The lowest was -3.30%. And the median was 3.18%.

ZBH's ROE % is ranked better than
69.13% of 813 companies
in the Medical Devices & Instruments industry
Industry Median: 0.25 vs ZBH: 8.32

Zimmer Biomet Holdings ROE % Historical Data

The historical data trend for Zimmer Biomet Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zimmer Biomet Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.57 -1.13 3.23 1.88 8.36

Zimmer Biomet Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.30 7.70 6.84 5.23 13.42

Competitive Comparison

For the Medical Devices subindustry, Zimmer Biomet Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zimmer Biomet Holdings ROE % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Zimmer Biomet Holdings's ROE % falls into.



Zimmer Biomet Holdings ROE % Calculation

Zimmer Biomet Holdings's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=1024/( (12020.3+12480.5)/ 2 )
=1024/12250.4
=8.36 %

Zimmer Biomet Holdings's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=1676.8/( (12510.8+12480.5)/ 2 )
=1676.8/12495.65
=13.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Zimmer Biomet Holdings  (NYSE:ZBH) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=1676.8/12495.65
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(1676.8 / 7760.4)*(7760.4 / 21357.1)*(21357.1 / 12495.65)
=Net Margin %*Asset Turnover*Equity Multiplier
=21.61 %*0.3634*1.7092
=ROA %*Equity Multiplier
=7.85 %*1.7092
=13.42 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=1676.8/12495.65
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (1676.8 / 1138) * (1138 / 1683.2) * (1683.2 / 7760.4) * (7760.4 / 21357.1) * (21357.1 / 12495.65)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.4735 * 0.6761 * 21.69 % * 0.3634 * 1.7092
=13.42 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Zimmer Biomet Holdings ROE % Related Terms

Thank you for viewing the detailed overview of Zimmer Biomet Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zimmer Biomet Holdings (Zimmer Biomet Holdings) Business Description

Traded in Other Exchanges
Address
345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Executives
Syed A. Jafry director 345 E. MAIN STREET, WARSAW IN 46580
Sreelakshmi Kolli director C/O ALIGN TECHNOLOGY INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 94131
Christopher B Begley director
Robert Hagemann director 3 GIRALDA FARMS, MADISON NJ 07940
Michael W Michelson director 2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Betsy J Bernard director 711 HIGH STREET, DES MOINES IA 50392-0300
Arthur J Higgins director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Chad F Phipps officer: Assoc. Gen. Counsel, Corp. Sec C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Zuilen Wilfred Van officer: Pres, Europe, M. East & Africa 345 E. MAIN STREET, WARSAW IN 46580
Paul A Stellato officer: VP, Controller & CAO C/O XYLEM INC, 1 INTERNATIONAL DRIVE, RYE BROOK NY 10573
Sang Yi officer: President, Asia Pacific 345 E. MAIN STREET, WARSAW IN 46580
Lori Winkler officer: SVP and CHRO 345 E. MAIN STREET, WARSAW IN 46580
Rachel Ellingson officer: SVP & CSO 345 E MAIN STREET, WARSAW K7 46580
Bryan C Hanson director, officer: President and CEO ZIMMER BIOMET HOLDINGS, 345 E. MAIN STREET, WARSAW IN 46580
Aure Bruneau officer: Group President 345 E. MAIN STREET, WARSAW IN 46580